Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia

Journal of Clinical Oncology

Volumn 14, Issue 1, 1996, Pages 18-24

  Smith, M ^a   Arthur, D ^a   Camitta, B ^a   Carroll, A J ^a   Crist, W ^a   Gaynon, P ^a   Gelber, R ^a   Heerema, N ^a   Korn, E L ^a   Link, M ^a   Murphy, S ^a   Pui, C H ^a   Pullen, J ^a   Reaman, G ^a   Sallan, S E ^a   Sather, H ^a   Shuster, J ^a   Simon, R ^a   Trigg, M ^a   Tubergen, D ^a   Uckun, F ^a   Ungerleider, R ^a   more..

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; B CELL LEUKEMIA; CANCER SURVIVAL; CHILD; CHILDHOOD CANCER; CLINICAL PROTOCOL; HIGH RISK PATIENT; HUMAN; IMMUNOPHENOTYPING; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; ONSET AGE; PRE B LYMPHOCYTE; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; T CELL LEUKEMIA;

EID: 9044226139     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.1.18     Document Type: Article

References (42)

1. Hammond D, Sather H, Nesbit M, et al: Analysis of prognostic factors in acute lymphoblastic leukemia. Med Pediatr Oncol 14:124-134, 1986
2. Lilleyman J, Eden O: United Kingdom Medical Research Council Acute Lymphoblastic Leukaemia (UKALL) Trials I-VIII: Clinical features and results of treatment in four groups of children with adverse prognostic features. Med Pediatr Oncol 14:182-186, 1986
3. Pui C-H, Crist W: Biology and treatment of acute lymphoblastic leukemia. J Pediatr 124:491-503, 1994
4. Crist W, Pullen J, Boyett J, et al: Clinical and biologic features predict a poor prognosis in acute lymphoid leukemias in infants: A Pediatric Oncology Group study. Blood 67:135-140, 1986
5. Mastrangelo R, Poplack D, Bleyer A, et al: Report and recommendations of the Rome Workshop concerning poor-prognosis acute lymphoblastic leukemia in children: Biologic bases for staging, stratification, and treatment. Med Pediatr Oncol 14:191-194, 1986
6. Harris M, Shuster J, Carroll A, et al: Trisomy of leukemic cell chromosomes 4 and 10 identifies children with B-progenitor cell acute lymphoblastic leukemia with a very low risk of treatment failure: A Pediatric Oncology Group study. Blood 79:3316-3324, 1992
7. Land V, Shuster J, Crist W, et al: Comparison of two schedules of intermediate-dose methotrexate and cytarabine consolidation therapy for childhood B-precursor cell acute lymphoblastic leukemia: A Pediatric Oncology Group study. J Clin Oncol 12:1939-1945, 1994
8. Amylon M, Carroll A, Link M, et al: Second malignancies in children treated with teniposide (VM-26) for T-cell lymphoid malignancy: A role for asparaginase? (A Pediatric Oncology Group Study). Blood 80:206a, 1992 (suppl 1, abstr)
9. Cherlow J, Steinherz P, Sather H, et al: The role of radiation therapy in the treatment of acute lymphoblastic leukemia with lymphomatous presentation: A report from the Childrens Cancer Group. Int J Radiat Oncol Biol Phys 27:1001-1009, 1993
10. Tubergen D, Gilchrist G, O'Brien R, et al: Improved outcome with delayed intensification for children with acute lymphoblastic leukemia and intermediate presenting features: A Childrens Cancer Group phase III trial. J Clin Oncol 11:527-537, 1993
11. Gaynon P, Steinherz P, Bleyer W, et al: Improved therapy for children with lymphoblastic leukemia and unfavorable presenting features: A follow-up report of the Childrens Cancer Group study CCG-106. J Clin Oncol 11:2234-2242, 1993
12. Tubergen D, Gilchrist G, O'Brien R, et al: Prevention of CNS disease in intermediate-risk acute lymphoblastic leukemia: Comparison of cranial radiation and intrathecal methotrexate and the importance of systemic therapy: A Childrens Cancer Group report. J Clin Oncol 11:520-526, 1993
13. Rivera G, Raimondi S, Hancock M, et al: Improved outcome in childhood acute lymphoblastic leukaemia with reinforced early treatment and rotational combination chemotherapy. Lancet 337:61-66, 1991
14. Pui C-H, Simone J, Hancock M, et al: Impact of three methods of treatment intensification on acute lymphoblastic leukemia in children: Long-term results of St Jude Total Therapy Study X. Leukemia 6:150-157, 1992
15. Schorin M, Blattner S, Gelber R, et al: Treatment of childhood acute lymphoblastic leukemia: Results of Dana-Farber Cancer Institute/Children's Hospital acute lymphoblastic leukemia consortium protocol 85-01. J Clin Oncol 12:740-747, 1994
16. Sather H: Age at diagnosis in childhood acute lymphoblastic leukemia. Med Pediatr Oncol 14:166-172, 1986
17. Look A, Roberson P, Williams D, et al: Prognostic importance of blast cell DNA content in childhood acute lymphoblastic leukemia. Blood 65:1079-1086, 1985
18. Trueworthy R, Shuster J, Look T, et al: Ploidy of lymphoblasts is the strongest predictor of treatment outcome in B-progenitor cell acute lymphoblastic leukemia of childhood: A Pediatric Oncology Group study. J Clin Oncol 10:606-613, 1992
19. Hiddemann W, Sykora R, Reiter A, et al: Definition of a favorable prognostic subgroup in childhood ALL by high-grade DNA aneuploidy: A BFM study group report. Proc Am Soc Clin Oncol 12:318, 1993 (abstr)
20. Miller D, Coccia P, Bleyer W, et al: Early response to induction therapy as a predictor of disease-free survival and late recurrence of childhood acute lymphoblastic leukemia: A report from the Childrens Cancer Study Group. J Clin Oncol 7:1807-1815, 1989
21. Gaynon P, Bleyer W, Steinherz P, et al: Day 7 marrow response and outcome for children with acute lymphoblastic leukemia and unfavorable presenting features. Med Pediatr Oncol 18:273-279, 1990
22. Schrappe M, Reiter A, Ludwig W, et al: Early response to corticosteroids as a prognostic factor in childhood acute lymphoblastic leukemia: A BFM study group report. Blood 70:208, 1987 (suppl 1, abstr)
23. Riehm H, Feickert H, Schrappe M, et al: Therapy results in five ALL-BFM studies since 1970: Implications of risk factors for prognosis. Haematol Blood Transfus 30:139-146, 1987
24. Reiter A, Schrappe M, Ludwig W-D, et al: Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86. Blood 84:3122-3133, 1994
25. Rautonen J, Hovi L, Siimes M: Slow disappearance of peripheral blast cells: An independent risk factor indicating poor prognosis in children with acute lymphoblastic leukemia. Blood 71:989-991, 1988
26. Gajjar A, Ribeiro R, Hancock M, et al: Persistence of circulating blasts after one week of multiagent chemotherapy confers a poor prognosis in childhood acute lymphoblastic leukemia. Blood 86:1292-1295, 1995
27. Raimondi S: Current status of cytogenetic research in child-hood acute lymphoblastic leukemia. Blood 81:2237-2251, 1993
28. Pui C-H, Frankel L, Carroll A, et al: Clinical characteristics and treatment outcome of childhood acute lymphoblastic leukemia with the t(4; 11)(q21;q23): A collaborative study of 40 cases. Blood 77:440-447, 1991
29. Crist W, Carroll A, Shuster J, et al: Philadelphia chromosome positive childhood acute lymphoblastic leukemia: Clinical and cytogenetic characteristics and treatment outcome. A Pediatric Oncology Group study. Blood 76:489-494, 1990
30. Fletcher J, Lynch E, Kimball V, et al: Translocation (9;22) is associated with extremely poor prognosis in intensively treated children with acute lymphoblastic leukemia. Blood 77:435-439, 1991
31. Crist W, Carroll A, Shuster J, et al: Poor prognosis of children with pre-B acute lymphoblastic leukemia is associated with the t(1; 19)(q23;p13): A Pediatric Oncology Group study. Blood 76:117-122, 1990
32. Pui C, Raimondi S, Hancock M, et al: Immunologie, cytogenetic, and clinical characterization of childhood acute lymphoblastic leukemia with the t(1; 19) (q23; p13) or its derivative. J Clin Oncol 12:2601-2606, 1994
33. Raimondi S, Behm F, Roberson P, et al: Cytogenetics of pre-B-cell acute lymphoblastic leukemia with emphasis on prognostic implications of the t(1; 19). J Clin Oncol 8:1380-1388, 1990
34. Izraell S, Henn T, Strobl H, et al: Expression of identical E2A/PBX1 fusion transcripts occurs in both pre-B and early pre-B immunological subtypes of childhood acute lymphoblastic leukemia. Leukemia 7:2054-2056, 1993
35. Privitera E, Kamps M, Hayashi Y, et al: Different molecular consequences of the 1; 19 chromosomal translocation in childhood B-cell precursor acute lymphoblastic leukemia. Blood 79:1781-1788, 1992
36. Steinherz P, Siegel S, Bleyer W, et al: Lymphomatous presentation of childhood acute lymphoblastic leukemia: A subgroup at high risk of early treatment failure. Cancer 68:751-758, 1991
37. Mahmoud H, Rivera G, Hancock M, et al: Low leukocyte counts with blast cells in cerebrospinal fluid of children with newly diagnosed acute lymphoblastic leukemia. N Engl J Med 329:314-319, 1993
38. Mahmoud H, Evans W, Liu Q, et al: Presence of leukemic blasts in the CSF at diagnosis predict CNS relapse in childhood ALL. Med Pediatr Oncol 23:189, 1994 (abstr)
39. Lauer S, Shuster J, Kirchner P, et al: Prognostic significance of cerebrospinal fluid (CSF) lymphobalsts (LB) at diagnosis (dx) in children with acute lymphoblastic leukemia (ALL). Proc Am Soc Clin Oncol 13:317, 1994 (abstr)
40. van den Berg H, Vet R, den Ouden E, et al: Prognostic significance of low cerebrospinal fluid lymphoblast counts at diagnosis in children with ALL/NHL: Possible benefit of dexamethasone. Med Pediatr Oncol 23:189, 1994 (abstr)
41. Gilchrist G, Tubergen D, Sather H, et al: Low numbers of CSF blasts at diagnosis do not predict for the development of CNS leukemia in children with intermediate-risk acute lymphoblastic leukemia: A Chidrens Cancer Group report. J Clin Oncol 12:2594-2600, 1994
42. Tubergen D, Cullen J, Boyett J, et al: Blasts in CSF with a normal cell count do not justify alteration of therapy for acute lymphoblastic leukemia in remission: A Childrens Cancer Group Study. J Clin Oncol 12:273-278, 1994